

**Daniel I. Simon, M.D.**  
**President, Academic & External Affairs and Chief Scientific Officer**  
**Ernie and Patti Novak Distinguished Chair Healthcare Leadership**  
**University Hospitals Health System**  
**Professor of Medicine and Senior Associate Dean for Academic Affairs**  
**Case Western Reserve University School of Medicine**



Daniel I. Simon is President of Academic & External Affairs and Chief Scientific Officer for the University Hospitals Health System (UH). Additionally, he is Professor of Medicine and Senior Associate Dean for Academic Affairs at Case Western Reserve University School of Medicine.

UH serves the needs of over one million patients through an integrated network of 23 hospitals (including five joint ventures), over 50 health centers and outpatient facilities and more than 200 physician offices in 16 counties throughout northern Ohio.

As President of Academic & External Affairs and Chief Scientific Officer, Dr. Simon leads the system's strategy and performance across the spectrum of research including basic, translational, clinical and health services/outcomes. UH is home to some of the most prestigious clinical and research programs in the nation, with a total research portfolio, in conjunction with Case Western Reserve University, of \$180 million and more than 3,000 active clinical trials and research studies underway.

He also oversees UH's graduate medical education and has primary responsibility for academic affiliations, including with Case Western Reserve University, Oxford University, NEOMED, Technion – Israel Institute of Technology, and National Taiwan University College of Medicine. Dr. Simon is also charged with elevating the system's performance in medical education and discovery to the highest levels and driving strategic philanthropy.

Additionally, Dr. Simon oversees the Harrington Discovery Institute at University Hospitals -- part of The Harrington Project for Discovery & Development and has executive leadership responsibility for the Office of Community Impact, Equity, Diversity and Inclusion.

Since joining UH in 2006 as Division Chief of Cardiovascular Medicine at UH Cleveland Medical Center and as Director of the UH Harrington Heart & Vascular Institute, Dr. Simon

has been promoted to increasing levels of responsibility as the system has grown, including President of UH Cleveland Medical Center, President of Community Medical Centers, and Chief Clinical & Scientific Officer for the entire health system.

Dr. Simon is a practicing cardiologist and continues to play a leading role in national and international clinical trials investigating new devices and anti-thrombotic drugs.

Prior to UH, Dr. Simon served as Associate Director of Interventional Cardiology at Brigham and Women's Hospital in Boston and was an Associate Professor of Medicine at Harvard Medical School.

A recipient of numerous research awards, Dr. Simon was elected into the American Society for Clinical Investigation, Association of University Cardiologists, and the Association of American Physicians. He is a recipient of the prestigious MERIT Award from the National Heart, Lung, and Blood Institute and the 2016 Distinguished Scientist Award from the American College of Cardiology. He is a Fellow of the American College of Cardiology, the American Heart Association, and the Society of Cardiac Angiography and Interventions.

He has published extensively in peer-reviewed basic science and clinical journals. Dr. Simon has served on the Editorial Boards of Circulation and Journal American College Cardiology and is currently appointed to the Editorial Board of JAMA Cardiology.

He graduated summa cum laude from Harvard College. After earning his medical degree from Harvard Medical School, he completed his internal medicine residency and cardiovascular medicine fellowship at Brigham and Women's Hospital and interventional cardiology training at Beth Israel Hospital, Harvard Medical School.

Dr. Simon is the Co-Founder of Sujana Biotech and Calida Therapeutics, start-up biotechnology companies developing novel monoclonal antibodies for a range of inflammatory and vascular disorders. The company's lead product is in the early preclinical phase of development.

Dr. Simon has served on the Board of Directors of Cleveland Institute of Art, Montefiore Senior Living Community, BioEnterprise, Playhouse Square, University Circle Inc. and Center for Health Affairs.